ArticleJournal of health, population, and nutrition2025
Global, regional, and national lifetime probabilities of urinary tract infections and interstitial nephritis from 1990 to 2021.
Article in Journal of health, population, and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Comparison of OneChoice AI-Based Clinical Decision Support Recommendations with Infectious Disease Specialists and Non-Specialists for Empirical Urinary Tract Infection Therapy in Lima, Peru.Diagnostics (Basel, Switzerland) · 2026Article
- Mechanistic insights into phage dynamics to overcome intracellular bacterial reservoirs in urinary tract infections.Npj viruses · 2026Article
- Optimizing antimicrobial stewardship in urology: a qualitative study on needs, values and requirements for clinical decision support.Infection prevention in practice · 2026Article
- Cefepime-enmetazobactam for complicated urinary tract infections: Redefining ESBL therapy.The Indian journal of medical research · 2026Review
- Drug Resistance Patterns and Pathogen Distribution in Patients with Urinary Tract Infection in Suzhou, China: A Five-Year Retrospective Study (2020-2024).Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Urinary tract infections (UTI) and interstitial nephritis (IN) are significant global health concerns, leaving a heavy burden to the healthcare system. UTI is one of the most common infections worldwide and IN is characterized by acute and chronic renal damage. This study aims to quantify the lifetime risk of developing and dying from UTI and IN across 204 countries from 1990 to 2021, utilizing data from the Global Burden of Disease 2021. We employed advanced statistical models, including the adjusted for multiple primaries method, Joinpoint trend analysis, and Autoregressive Integrated Moving Average (ARIMA) models, to assess temporal trends and forecast future risks. Results revealed a global lifetime risk of developing UTI and IN at 93.70% in 2021, with higher risks in females (96.05%) compared to males (77.27%). The global lifetime risk of dying from UTI and IN at 0.50%. High Socio-demographic Index (SDI) regions exhibited higher developing risks, while low-SDI regions showed significant upward trends. Gender disparities were evident, with females consistently experiencing higher risks. The ARIMA model projected a persistent upward trend in UTI and IN risks over the next 3 decades, emphasizing the need for targeted public health interventions. These findings highlight the importance of addressing UTI and IN through improved healthcare infrastructure, early screening, and preventive measures, particularly in high-risk populations and regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.